A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

NCT04198363 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Helicobacter Pylori

Interventions

DRUG: Vonoprazan
DRUG: Amoxicillin
DRUG: Clarithromycin
DRUG: Bismuth Potassium citrate
DRUG: Esomeprazole

Sponsor

Takeda